A researcher who works for Janssen Scientific Affairs, a division of Johnson & Johnson’s Janssen Pharmaceuticals, conducted a year-long study comparing the company’s type 2 diabetes drug Invokana with the diabetes drug glimepiride and determined that Invokana was better at improving glycemic control, blood pressure and weight loss than glimepiride in patients with type 2 diabetes. The study was presented last month at the AACE Annual Scientific and Clinical Congress. Invokana, known chemically as canagliflozin, is in a newer class of type 2 diabetes medications known as sodium-glucose cotransporter-2 (SGLT2) inhibitors. They lower blood sugary by causing the kidneys to ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.